News & Updates

Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024 byStephen Padilla

Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.

Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
Cervical cancer, leukaemia survivors face heightened risks during pregnancy
Cervical cancer, leukaemia survivors face heightened risks during pregnancy
06 Aug 2024 byJairia Dela Cruz

Pregnancies in women who have survived cervical cancer or leukaemia should be considered high-risk due to the potential for multiple severe obstetric complications, as reported in a study.

Cervical cancer, leukaemia survivors face heightened risks during pregnancy
06 Aug 2024